BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
NOVO-NORDISK A/S (NY: NVO)
45.25 USD  UNCHANGED
Official Closing Price  /  Updated: 6:40 PM EDT, Apr 22, 2014  /  Add to My Watchlist      
(NVO) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 23, 2014
(Top Foreign Stocks, 12/24/13)
Danish drug maker Novo Nordisk (NVO) announced a stock split in the ratio of 5:1 on its ADRs recently. The effective date of the split is Jan 9, 2014 and the record date is Jan 3, 2014. From the...(read more)
(Jutia Group, 12/16/13)
[at Motley Fool] - Novo Nordisk (NVO) and Eli Lilly (LLY) are giants when it comes to treating diabetes, but is one a better buy than the other? Read more on this. Eli Lilly and Company (LLY), valued at $53.32B, started the session at $49.61.   Today’s price range has [...]
(Stock Blog Hub, 8/19/13)
Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study. Paradigm 2 evaluated N9-GP, a long-acting FIX...(read more)
Novo Nordisk A/S (NVO) Company Overview

There is no analysis for NVO yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here